Patients with advanced lung cancer may have a safer chemotherapy treatment option. TAXOL (paclitaxel) plus Paraplatin (carboplatin), administered in a novel weekly regimen, offers a safe and ...

Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly paclitaxel considered equivalent to 3-weekly docetaxel. The CALGB 40502 ...

CHICAGO, Illinois — In a result that should change clinical practice, a low-dose weekly schedule of the breast cancer chemotherapy stalwart paclitaxel appears to be less toxic than the standard ...

PURPOSE: We investigated 96-hour paclitaxel infusion combined with weekly (days eight and 15) vinorelbine as salvage therapy for metastatic breast cancer in anthracycline-exposed patients. All ...

CHICAGO -- Breast cancer patients obtained the same disease control with less toxicity when they received weekly low-dose chemotherapy instead of a higher dose given every 2 weeks, results of a random ...

The phase III trial, which enrolled 2233 patients, compared two dose-dense chemotherapy regimens: Weekly nab-paclitaxel (125 mg/m 2 for eight cycles) vs biweekly solvent-based paclitaxel (175 mg/m ...

Thirty-six patients (97,3%) received a first chemotherapy line based on platinum and 1 patient (2,7%) without platinum. All patients were treated with weekly paclitaxel (60 – 80 mg/m2) at second line ...

Nature Reviews Clinical Oncology - Weekly adjuvant paclitaxel improves survival after standard chemotherapy in breast cancer Skip to main content Thank you for visiting nature.com.

Women whose breast cancer may have spread survive a bit longer with weekly infusions of the drug Taxol than less-frequent treatments or treatment with a similar drug, researchers reported on ...

The 16% of women in the study who did not take bevacizumab and had weekly chemo had 14.2 months without signs of their ovarian cancer progressing, compared to 10.3 months for those getting monthly ...

Sept. 21 -- SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin ...